Economic impact of new interventional therapies: are we asking the right questions?
Kong
David F
DF
Mark
Daniel B
DB
D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000191:economics* / Q000628:therapy*; D003362:Cost-Benefit Analysis; D004617:Embolism / Q000191:economics* / Q000517:prevention & control*; D006493:Heparin / Q000191:economics* / Q000627:therapeutic use*; D006629:Hirudins / Q000031:analogs & derivatives* / Q000191:economics*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D010446:Peptide Fragments / Q000191:economics* / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000191:economics / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000191:economics* / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use*; D012501:Saphenous Vein / Q000473:pathology* / Q000601:surgery*
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin